attyloid GmbH
attyloid GmbH develops and commercializes ultra-sensitive biomarker detection technology for neurodegenerative and related diseases.
About
attyloid GmbH is a German biotech company focused on advancing biomarker detection for neurodegenerative diseases such as Alzheimer's and Parkinson's. Originating as an academic spin-off, attyloid leverages its proprietary sFIDA (surface-based Fluorescence Intensity Distribution Analysis) platform, a technology capable of ultrasensitive, quantitative detection and sizing of protein aggregates—key biomarkers of central nervous system (CNS) and metabolic disorders. Their technology supports drug development, mechanism of action evaluation, patient stratification, therapy monitoring, and research into protein aggregation. attyloid collaborates with pharmaceutical and biotech partners in innovative risk-sharing research models, contributing significant scientific advances and publications to the field.
Products & Services
- sFIDA platform technology for detecting protein oligomers and aggregates
- CNS biomarker assays for Alzheimer's and Parkinson's disease
- Biomarker assay development services
- Subvisible particle analysis for biologicals R&D and quality control
- Viral particle analysis for vaccine and viral therapeutics development
- Custom assay development based on proprietary technology
- Clinical and preclinical biomarker testing services
Use Cases & Case Studies
- Validated Alzheimer's therapy in beagle models using sFIDA for tau aggregate quantification
- Blood-based detection of Aβ oligomers in large cohorts for early Alzheimer's diagnostics
- Non-invasive fecal biomarker detection for Alzheimer's disease
- Quantitation of protein aggregates in psychiatric and metabolic disorders
- Viral particle counting for vaccine and gene therapy R&D
Partnerships & Collaborations
- Collaboration with the DELCODE team at DZNE (German Center for Neurodegenerative Diseases)
- Multiple academic collaborations in published studies
- Collaboration with pharmaceutical, biotech, and biosimilar companies as risk-sharing partners
Awards & Recognition
- Düsseldorf Citizen of the Year 2017 (for CEO, Dr. Oliver Bannach)
Contact Information
Certifications & Compliance
- Implementation of internal quality control (IQC) standards in biomarker assays